Seamus Fernandez

“So I'm going to do the non-obesity question. Kasimla is actually, you know, starting to show the prospect of becoming a blockbuster product and, you know, starting to grow faster, maybe a little bit faster overseas.”

“So, my question is actually on your approach in kidney disease.”

“So I just wanted to get a sense of the information that you guys have on a blinded basis as it relates to weight gain throughout the native pre-study and if you might be able to kind of share what's with your expectations for potential weight gain.”

“Just, I guess, first off, you know, as you're speaking with KALS and doing your outreach, what's really resonating with KALS about the profile here? And then second, you know, congrats to Terry for joining.”

“You know, I believe maybe you guys could just update us on when the last patient visit was. And, you know, what are the kind of key factors that kind of need to be completed to lock the database?”